Generates revenue from proprietary specialty plasma-derived therapeutics through product sales and royalties, supplemented by sales of collected plasma to third parties. Also earns revenue by distributing third-party pharmaceuticals and biosimilars.
Geographic Exposure
United States62.44%
Israel15.54%
Latin America11.56%
Canada5.88%
Europe3.07%
Asia1.48%
Revenue Drivers
Proprietary plasma-derived therapies
Sells proprietary plasma-derived biologics, earns royalties, and sells collected plasma.
CORE87.9%
Third-party drug distribution
Markets and distributes imported pharmaceuticals and biosimilars.
SIGNIFICANT12.1%
End Markets
Pharmaceutical wholesalers
Hospitals and transplant centers
Health maintenance organizations (payors/providers)
Government health ministries
International health organizations (tender buyers)
Hyper-immune plasma collectionPlasma fractionation and IgG purification know-howTechnology transfer and insourcing of biologics manufacturingTender-based contracting for biologics supplyCold-chain logistics and third-party 3PL fulfillmentInvestigator-initiated clinical studies support+1 more
Activities
cGMP biologics manufacturing and plasma fractionation
Plasma collection and donor center operations
Commercialization, marketing, and distribution (direct and via partners)
